How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma

Liver International

Volumn 30, Issue 4, 2010, Pages 496-498

  Ryu, Soo Hyung ^a   Chung, Young Hwa ^b  

^a Inje University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Multidrug resistance; Nanoparticle; Tumour necrosis factor

Indexed keywords

ABC TRANSPORTER; ALPHA INTERFERON; BREAST CANCER RESISTANCE PROTEIN; BROMOCRIPTINE; CISPLATIN; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; HYDROXYAPATITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RECOMBINANT MUTANT HUMAN TUMOR NECROSIS FACROR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EDITORIAL; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, MDR; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950608353     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02215.x     Document Type: Editorial

References (21)

1. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 2009, 29:143-7.
2. Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009, 29:148-58.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-36.
4. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008, 14:6437-41.
5. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006, 13:1859-76.
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev 2002, 2:48-58.
7. Wang J, Chan J Y-W, Fong C-C. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int 2009, 29:1338-47.
8. Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007, 27:155-62.
9. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-76.
10. Watanuki A, Ohwada S, Fukusato T. Prognostic significance of DNA topoisomerase II alpha expression in human hepatocellular carcinoma. Anticancer Res 2002, 22:1113-9.
11. Li G, Dong S, Qu J. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumor necrosis factor-α in chemotherapy of multidrug-resistant hepatocellular carcinoma. Liver Int 2010, 30:585-92.
12. Hill ADK, Redmond HP, Croke DT, Grace PA, Bouchier-Hayes D. Cytokines in tumor therapy. Br J Surg 1992, 79:990-7.
13. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Phamacol Sin 2008, 29:1275-88.
14. Shibata H, Yoshioka Y, Ikemizu S. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004, 10:8293-300.
15. Lucas R, Montesano R, Pepper MS. Lectin-deficient TNF mutants display comparable anti-tumor but reduced pro-metastatic potential as compared to the wild-type molecule. Int J cancer 2001, 91:543-9.
16. Ding L, Chen X-P, Zhang Z-W. Synergistic effect of bromocriptine and tumor necrosis factor-α on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm. World J Gastroenterol 2005, 11:5621-6.
17. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62:479-83.
18. Yeo W, Mok TS, Zee B. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97:1532-8.
19. Azria D, Dorvillius M, Gourgou S. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys 2003, 55:1363-73.
20. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008, 34:592-602.
21. Huesker M, Folmer Y, Schneider M. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology 2002, 36:874-84.